Genprex announced that its research collaborators presented positive preclinical data for Reqorsa Immunogene Therapy and NPRL2 gene therapy, which both utilize the company’s non-viral Oncoprex Delivery System for the treatment of lung cancer. These studies were presented at the 2024 American Association for Cancer Research Annual Meeting, which is being held April 5-10, 2024 in San Diego, California.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GNPX:
- Genprex expands clinical trial sites for study of Reqorsa in lung cancer
- Genprex initiated with a Buy at H.C. Wainwright
- Genprex announces $6.5M registered direct offering priced at the market
- Genprex to sell 1.54M shares at $4.215 in registered direct offering priced ATM
- Genprex to sell 1.54M shares at $4.215 per share
